Literature DB >> 7364914

Paired-ion chromatographic analysis of tamoxifen and two major metabolites in plasma.

Y Golander, L A Sternson.   

Abstract

A method is described for the clinical analysis of the non-steroidal anti-estrogenic, antineoplastic agent, tamoxifen and its 4-hydroxy and N-desmethyl metabolites in human plasma. The analytes are extracted from biological fluid with diethyl ether and subsequently converted to fluorescent phenanthrene derivatives by irradiation with UV light. The fluorophores are separated by paired-ion chromatography on a reversed-phase (C18) column. Spectrofluorometric monitoring of the column eluent allows quantitation of analytes as their phenanthrene derivatives to levels of 100 pg/ml of plasma.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7364914     DOI: 10.1016/s0378-4347(00)81267-0

Source DB:  PubMed          Journal:  J Chromatogr


  10 in total

1.  Serum elimination half-life of tamoxifen and its metabolites in patients with advanced breast cancer.

Authors:  D de Vos; P H Slee; D Stevenson; R J Briggs
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

Review 2.  Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.

Authors:  P E Lønning; E A Lien; S Lundgren; S Kvinnsland
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

3.  The bioavailability of Tamoplex (tamoxifen). Part 3. A steady-state study in breast cancer patients.

Authors:  P H Slee; D De Vos; D Chapman; D Stevenson
Journal:  Pharm Weekbl Sci       Date:  1988-02-19

4.  The development of tamoxifen for breast cancer therapy: a tribute to the late Arthur L. Walpole.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1988-07       Impact factor: 4.872

Review 5.  New insights into the metabolism of tamoxifen and its role in the treatment and prevention of breast cancer.

Authors:  V Craig Jordan
Journal:  Steroids       Date:  2007-07-27       Impact factor: 2.668

6.  Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer.

Authors:  S R Johnston; B P Haynes; N P Sacks; J A McKinna; L J Griggs; M Jarman; M Baum; I E Smith; M Dowsett
Journal:  Breast Cancer Res Treat       Date:  1993-12       Impact factor: 4.872

Review 7.  Metabolites of tamoxifen in animals and man: identification, pharmacology, and significance.

Authors:  V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1982       Impact factor: 4.872

8.  Evaluation of tamoxifen and metabolites by LC-MS/MS and HPLC methods.

Authors:  D D Heath; S W Flat; A H B Wu; M A Pruitt; C L Rock
Journal:  Br J Biomed Sci       Date:  2014       Impact factor: 3.829

9.  Optimised analysis of tamoxifen and its main metabolites in the plasma and cytosol of mammary tumours.

Authors:  G Milano; M C Etienne; M Frenay; R Khater; J L Formento; N Renee; J L Moll; M Francoual; M Berto; M Namer
Journal:  Br J Cancer       Date:  1987-05       Impact factor: 7.640

10.  Effect of tamoxifen upon cell DNA analysis by flow cytometry in primary carcinoma of the breast.

Authors:  A D Baildam; J Zaloudik; A Howell; D M Barnes; M Moore; R A Sellwood
Journal:  Br J Cancer       Date:  1987-05       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.